Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) has stated that the company does not have any drugs or research and development technologies available for medical beauty or cosmetics [1] Company Summary - QianYuan Pharmaceutical clarified its position regarding the absence of products related to medical beauty and cosmetics [1]

Company Overview - QianYuan Pharmaceutical (SZ 300254) announced on September 22 that its fifth board meeting was held via telecommunication to review the proposal for bank credit borrowing [1] - As of the report date, QianYuan Pharmaceutical has a market capitalization of 2.6 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of QianYuan Pharmaceutical is as follows: - Pharmaceutical manufacturing accounts for 96.68% - DNA gene preservation and prenatal environment testing services account for 1.93% - Health food accounts for 0.79% - Other businesses account for 0.51% - Commercial activities account for 0.1% [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-065 山西仟源医药集团股份有限公司 第五届董事会第三十四次会议决议公告 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》、《公司章程》等的相关规定， 本议案无须提交公司股东会审议。公司董事会授权管理层办理本次授信借款的具 体事宜并签署相关协议。 三、董事会意见 经审议，与会董事认为：公司向山西银行股份有限公司大同分行申请授信借 款不超过人民币 12,000 万元，有利于满足公司经营发展的需要，促进公司业务 的持续稳定发展。同时全资子公司保灵集团、仟源保灵以及公司董事长黄乐群提 供连带责任保证担保符合《深圳证券交易所创业板股票上市规则》、《上市公司自 律监管指引第 2 号——创业板上市公司规范运作》以及《公司章程》等相关法律、 法规和规范性文件的规定，不存在损害公司和股东利益的情况。 表决结果：同意 9 票；反对 0 票；弃权 0 票 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有 ...

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is actively engaging with institutional investors regarding its smoking cessation product, Varenicline Tartrate Tablets, highlighting its multi-channel sales strategy and market expansion efforts [1] Group 1: Product and Sales Strategy - The product utilizes a dual-brand strategy (Parique and Family Pharmacist) and a multi-channel sales model, covering over 100,000 chain stores and more than 600 hospitals, with online sales focused on platforms like JD, Alibaba, and Meituan [1] - Currently, the largest sales volume comes from offline chain channels, while hospital sales have not yet met company expectations [1] Group 2: Market Expansion and Effectiveness - The time to see results from entering new cities or regions depends on the execution and operational capabilities of the pharmacies, with effective pharmacies showing results in 2 to 3 months, while less capable ones may take longer [1] - Smokers typically see effects within days of using Varenicline Tartrate Tablets, but due to nicotine addiction's complex nature, there is a notable relapse rate, prompting the company to recommend adherence to the treatment regimen [1] Group 3: Competitive Landscape - The potential re-entry of Pfizer's smoking cessation drug into the Chinese market could enhance consumer awareness and market education, benefiting the overall market size due to Pfizer's strong brand influence and marketing capabilities [1]

Group 1: Sales Channels and Performance - The company’s smoking cessation drug, Varenicline Tartrate Tablets, utilizes a dual-brand strategy (PariKe and Family Pharmacist) and multiple sales channels, including over 100,000 chain stores and more than 600 hospitals, with online sales primarily through JD, Alibaba, and Meituan [2] - The largest sales volume for the smoking cessation drug currently comes from offline chain channels [2] - Sales in hospital channels have not met company expectations, as most hospitals only have smoking cessation clinics available for one or two half-days a week [3] Group 2: Market Expansion and Effectiveness - The time required to see results from expanding the drug to new cities or regions depends on the pharmacy's execution; well-managed pharmacies may show improvement in 2 to 3 months, while others may take longer [3] - Smokers using Varenicline Tartrate Tablets generally see effects within a few days, but a significant proportion experience relapse due to various physiological and psychological factors [3] Group 3: Competitive Landscape - If Pfizer re-enters the Chinese market with its smoking cessation drug, the company believes it would positively impact the market by increasing consumer awareness and expanding the overall market size [3]

Group 1: Product Efficacy and Side Effects - Varenicline tartrate tablets are recommended by WHO and various clinical guidelines for smoking cessation, with clinically validated efficacy [2] - The incidence of nausea as a side effect is approximately 20%, typically transient within the first 1-2 weeks of use [2][3] Group 2: Insurance and Promotion - Smoking cessation medications are generally not included in the medical insurance directory as per the 2020 interim measures [3] - The company has established a "Quit Smoking with Me" WeChat public account to promote smoking cessation knowledge [3] Group 3: Sales and Market Expansion - The company has expanded its smoking cessation product to over 100,000 retail stores, with over 60,000 maintained by the company's team [3] - Each sales representative currently covers approximately 400 stores, with plans to increase the team to around 200 members, aiming for coverage of 600 stores each [3] - The highest revenue-generating product is the urological medication, Tamsulosin hydrochloride sustained-release capsules, which has maintained double-digit growth for several years [3]

Group 1 - The core point of the article is that Qianyuan Pharmaceutical announced a board meeting to discuss the proposal for engaging in financing leasing business [1] - For the year 2024, the revenue composition of Qianyuan Pharmaceutical is as follows: 96.68% from pharmaceutical manufacturing, 1.93% from DNA gene preservation and prenatal environment testing services, 0.79% from health food, 0.51% from other businesses, and 0.1% from commercial activities [1] - As of the report date, Qianyuan Pharmaceutical has a market capitalization of 2.7 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, which has been acknowledged by both Chinese and American officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-063 山西仟源医药集团股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日 以邮件方式发出第五届董事会第三十三次会议通知及议案，2025 年 9 月 15 日以 通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董事 9 名，实际出席董事 9 名。出席会议人员对本次会议的召集、召开方式无异议。 本次会议的召集、召开符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式审议通过《关于公司开展融资租赁业务的议案》。 经审议：我们认为公司本次办理融资租赁售后回租业务，能够盘活公司固定 资产，拓宽融资渠道，优化融资结构，为生产经营提供长期资金支持。本次开展 融资租赁售后回租业务，不影响公司相关资产的正常使用，不会对公司的生产经 营产生 ...

一、融资租赁业务概述 为盘活现有资产、拓宽融资渠道、满足日常经营的资金需求，山西仟源医药 集团股份有限公司（以下简称"公司"）将开展融资租赁售后回租业务，公司使 用部分固定资产采用售后回租的方式与向平安点创国际融资租赁有限公司（以下 简称"平安点创"）申请融资额不超过 5,000 万元，期限 2 年半。应平安点创要 求，由控股子公司浙江仟源海力生制药有限公司及公司总裁赵群先生为公司在平 安点创的上述融资租赁业务提供连带保证责任。融资租赁事项的相关租赁利率、 租金及支付方式等具体内容以实际签订的协议为准。 公司已于2025年9月15日召开第五届董事会第三十三次会议，审议通过了《关 于公司开展融资租赁业务的议案》。根据《深圳证券交易所创业板股票上市规则》、 《公司章程》等相关规定，本次审议事项属于公司董事会决策权限，无需提交公 司股东会审议。同时，董事会授权总裁或其指派的相关人员在批准的额度内办理 公司融资租赁业务的一切事宜。 公司与平安点创无关联关系，本次融资租赁售后回租事项不构成关联交易， 亦不构成《上市公司重大资产重组管理办法》中规定的重大资产重组。 证券代码：300254 证券简称：仟源医药 公告编号：2 ...

Group 1 - The core point of the article is that Zhao Qun, a major shareholder and the president of Qianyuan Pharmaceutical, increased his stake in the company, becoming the largest single shareholder [1] - Zhao Qun acquired 2,079,900 shares through centralized bidding from September 11 to 12, 2025, representing 0.84% of the total share capital [1] - After the acquisition, Zhao Qun holds a total of 15,781,792 shares, which is 6.36% of the company [1] Group 2 - Zhao Qun's action was supported by his concerted action partner, Huang Lequn, who holds 5,465,060 shares, accounting for 2.20% of the total shares [1] - Together, Zhao Qun and Huang Lequn own a combined total of 8.56% of the company [1] - Following this change, the company still has no actual controller or controlling shareholder [1]